Status:
UNKNOWN
tDCS in Tourette (TIC-TDCS)
Lead Sponsor:
University of Calgary
Conditions:
Tourette Syndrome
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
Double-blind randomized, sham-controlled clinical trial of 1 mA bilateral supplementary motor area in adolescents/adults with Tourette syndrome (TS). The primary objectives are to assess and quantify ...
Eligibility Criteria
Inclusion
- Participants who meet Diagnostic and Statistical Manual of Mental Disorders criteria for TS (APA, DSM V).
- 16 years of age or older.
- A "moderately ill" or worse score on the Clinical Global Impression Severity scale (CGI-S).
- A total motor tic or vocal tic severity score greater or equal to 15/25 on the Yale Global Tic Severity Scale (YGTSS) or a combined score greater than 22/50.
- Participants should be either un-medicated or on stable medication treatment for tics for the previous 3 months. If receiving botulinum toxin treatment, their enrolment should be at least 16 weeks after the last treatment session.
- Psychiatric comorbidities should be clinically stable; treatment has not changed in the last 3 months.
Exclusion
- Participants will be excluded from the study if they meet any of the following criteria:
- Have a metal object/implant in their brain, skull, scalp, or neck.
- Have an implantable device (e.g., cardiac pacemaker).
- Have a diagnosis of epilepsy or cardiac disease.
- Have a history of traumatic brain injury, learning disability or dyslexia.
- Have a severe impediment in vision or hearing.
Key Trial Info
Start Date :
May 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03401996
Start Date
May 1 2018
End Date
April 30 2021
Last Update
March 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Clinical Neurosciences, University of Calgary
Calgary, Alberta, Canada, T2N 4N1